Highlights

• Cohort 4 of the SECuRE trial is the first to assess multiple cycles of ⁶⁷Cu-SAR-bisPSMA at the highest dose of 12GBq.
• The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 doses of ⁶⁷Cu-SAR-bisPSMA. Two of these participants had completed the dose limiting toxicity (DLT) period and...